Insuman Basal Solostar (Insulin Human)

Insulin human mimics the natural hormone insulin. It binds to insulin receptors on muscle, fat and liver cells, activating a cascade that promotes glucose uptake, glycogen synthesis and lipid storage while suppressing hepatic glucose production. This reduces circulating blood glucose and supports normal metabolic function.

The dose of Insuman Basal Solostar is individualized. A qualified prescriber determines the appropriate amount based on the patient’s age, weight, current glycaemic control, diet, activity level and concomitant therapies. Patients should follow the prescribing information and adjust only under medical supervision.

Insulin is generally considered the treatment of choice for diabetes in pregnancy because it does not cross the placenta in significant amounts. However, the safety of Insuman Basal Solostar specifically should be evaluated by the treating obstetrician and endocrinologist, and the benefits and risks discussed with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and any required import documentation.

Insuman Basal Solostar contains human insulin, whereas many newer basal insulins are insulin analogues with altered pharmacokinetics. Human insulin has a well‑established safety profile and is often less expensive, but analogue products may offer flatter glucose‑lowering curves and reduced risk of nocturnal hypoglycaemia for some patients.

The product should be stored at 2‑8 °C (refrigerated) in its original carton, protected from light. Do not freeze or shake the vial. Once in use, it may be kept at room temperature (up to 30 °C) for a limited period as specified in the package insert, but must be discarded after the recommended in‑use time.

Insuman Basal Solostar is administered by subcutaneous injection, typically into the abdomen, thigh or upper arm. The injection should be given once daily at the same time each day, with site rotation to reduce lipodystrophy. Patients must be trained on proper technique and needle disposal.

The most serious risks include severe hypoglycaemia, which can cause seizures, loss of consciousness or death if not treated promptly, and rare allergic reactions such as anaphylaxis. Patients should be educated to recognize early signs of hypoglycaemia and to have rapid‑acting carbohydrate sources available.

Insuman Basal Solostar is contraindicated in individuals with a known hypersensitivity to human insulin or any excipients in the formulation. It should also be avoided in patients experiencing hypoglycaemia until glucose levels are corrected, and used with caution in those with severe renal or hepatic impairment.